BETHKIS 300 mg/4mL
tobramycin · SOLUTION · Chiesi USA, Inc.
BETHKIS is a solution containing tobramycin at 300 mg/4mL, taken respiratory (inhalation). Manufactured by Chiesi USA, Inc..
Key Facts
- Brand Name
- BETHKIS
- Generic Name
- tobramycin
- NDC Code (Product)
10122-820- Manufacturer
- Chiesi USA, Inc.
- Strength
- 300 mg/4mL
- Dosage Form
- SOLUTION
- Route
- RESPIRATORY (INHALATION)
- Marketing Status
- Application #
- NDA201820
- Drug Class
- Aminoglycoside Antibacterial [EPC]
- Marketing Start
- 04/15/2013
Recall History
Kroger Specialty Pharmacy, Inc.
Lack of Processing Controls.
Side Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
1 INDICATIONS AND USAGE BETHKIS is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV 1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )] . BETHKIS is an inhaled aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa . ( 1 ) Safety and efficacy have not been demonstrated in patients under the age of six years, patients with a forced expiratory volume in one second (FEV 1 ) less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia . ( 1 )
Dosage & Administration
2 DOSAGE AND ADMINISTRATION For oral inhalation only ( 2.1 ) Administer the entire contents of one ampule twice daily by oral inhalation in repeated cycles of 28 days on drug, followed by 28 days off drug. ( 2.1 ) 2.1 Dosage Bethkis is for oral inhalation only [see Dosage and Administration ( 2.2 )] . The recommended dosage of BETHKIS for patients six years of age and older is to administer one single-use ampule (300 mg/4 mL) twice daily by oral inhalation in repeated cycles of 28 days on drug, followed by 28 days off drug. The doses should be taken as close to 12 hours apart as possible and not less than 6 hours apart. The 300 mg/4 mL dose of BETHKIS is the same for patients regardless of age or weight. BETHKIS has not been studied in patients less than six years old. If patients miss a dose, they should take it as soon as possible anytime up to 6 hours prior to their next scheduled dose. If less than 6 hours remain before the next dose, wait until their next scheduled dose. 2.2 Administration Instructions BETHKIS is administered by oral inhalation using a hand-held PARI LC PLUS Reusable Nebulizer with a PARI Vios Air compressor over an approximately 15 minute period and until spu…
Contraindications
4 CONTRAINDICATIONS BETHKIS is contraindicated in patients with a known hypersensitivity to any aminoglycoside. BETHKIS is contraindicated in patients with a known hypersensitivity to any aminoglycoside. ( 4 )
Drug Interactions
7 DRUG INTERACTIONS Concurrent and/or sequential use of BETHKIS with other drugs with neurotoxic, nephrotoxic or ototoxic potential should be avoided. ( 7.1 ) BETHKIS should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. ( 7.2 ) 7.1 Drugs with Neurotoxic, Nephrotoxic, or Ototoxic Potential Concurrent and/or sequential use of BETHKIS with other drugs with neurotoxic, nephrotoxic, or ototoxic potential should be avoided. 7.2 Diuretics Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. Therefore, BETHKIS should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol. The interaction between inhaled mannitol and BETHKIS has not been evaluated.
Adverse Reactions
6 ADVERSE REACTIONS Common adverse reactions (more than 5%) occurring more frequently in BETHKIS patients are forced expiratory volume decreased, rales, red blood cell sedimentation rate increased, and dysphonia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA, Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of drugs cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to BETHKIS in two placebo-controlled studies in 305 cystic fibrosis patients. Patients receiving BETHKIS ranged in age from 6 to 31 years. In Study 1, an eight week study, 29 patients received BETHKIS versus 30 patients who received placebo for a total of four weeks on drug and four weeks off drug. All patients were ≤ 30 years of age (mean age 12.6 years) and 46% were females. 52.5% of patients were 6 to 12 years of age while 30.5% of patients were 13-17 years old. Only 16.5% of patients were adults (> 17 year…
Frequently Asked Questions
What is BETHKIS used for?
BETHKIS contains tobramycin. It is a solution taken respiratory (inhalation). Consult your doctor for specific uses.
Is BETHKIS a controlled substance?
BETHKIS is not classified as a controlled substance by the DEA.
What is the generic name for BETHKIS?
The generic name for BETHKIS is tobramycin. There are 11 other brand versions of tobramycin.
What is the NDC code for BETHKIS 300 mg/4mL?
The NDC (National Drug Code) for BETHKIS 300 mg/4mL is 10122-820, listed by Chiesi USA, Inc..
Other Tobramycin Brands
See all →- Tobramycin Inhalation Solution300 mg/5mL43598-605
- Tobramycin and Dexamethasone1 mg/mL50090-1136
- Tobramycin and Dexamethasone1 mg/mL50090-1914
- TOBRAMYCIN AND DEXAMETHASONE1 mg/mL50090-7267
- Tobramycin Ophthalmic Solution3 mg/mL62332-518
- Tobramycin40 mg/mL63323-306
- TOBRAMYCIN AND DEXAMETHASONE1 mg/mL63629-9570
- TOBRAMYCIN300 mg/5mL70756-604
- Tobramycin3 mg/mL76420-791
- Tobramycin300 mg/5mL60687-731
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)